Department of Pediatrics, Weill Cornell Medical College, New York, New York 10065, USA.
J Clin Invest. 2011 Jan;121(1):14-6. doi: 10.1172/JCI45692. Epub 2010 Dec 22.
Dysregulated Hedgehog (Hh) signaling has been implicated in a growing number of human cancers. To date, most antagonists of this signaling pathway that have been developed target the Hh receptor Smoothened. However, these are predicted to have minimal effect when the pathway is activated as a result of dysregulation downstream of this receptor. In this issue of the JCI, Beauchamp and colleagues provide preclinical evidence that arsenic trioxide, a drug FDA approved for the treatment of acute promyelocytic leukemia, inhibits the growth of Ewing sarcoma and medulloblastoma cells by targeting GLI family zinc finger (GLI) proteins, which are Hh signaling pathway components downstream of Smoothened.
Hedgehog (Hh) 信号通路失调与越来越多种人类癌症相关。迄今为止,已开发出的大多数针对该信号通路的拮抗剂都以 Hh 受体 Smoothened 为靶点。然而,当该受体下游的失调导致该通路被激活时,这些拮抗剂预计效果甚微。在本期 JCI 中,Beauchamp 及其同事提供了临床前证据,表明三氧化二砷,一种经美国食品药品监督管理局批准用于治疗急性早幼粒细胞白血病的药物,通过靶向 Gli 家族锌指 (GLI) 蛋白抑制尤文肉瘤和髓母细胞瘤细胞的生长,GLI 蛋白是 Smoothened 下游的 Hh 信号通路成分。